Document is current
Any future updates will be listed below
-
Authors
Dzhus, Mariia https://orcid.org/0000-0002-2077-4295
Ehlers, Lisa https://orcid.org/0000-0001-8737-001X
Wouters, Marjon
Jansen, Katrien
Schrijvers, Rik https://orcid.org/0000-0002-4261-6220
De Somer, Lien https://orcid.org/0000-0002-8488-5090
Vanderschueren, Steven https://orcid.org/0000-0002-4003-5465
Baggio, Marco https://orcid.org/0000-0001-6708-9925
Moens, Leen
Verhaaren, Benjamin
Lories, Rik https://orcid.org/0000-0002-5986-3092
Bucciol, Giorgia https://orcid.org/0000-0001-5004-0738
Meyts, Isabelle https://orcid.org/0000-0003-1214-0302
-
Funding
Funding for this research was provided by:
KU Leuven (C16/18/007)
KU Leuven (C14/20/117, DOAC14/19/092, IDN/20/019)
FWO (G0E8420N)
FWO (18B2122N)
FWO (G099922N and G0B2120N)
FWO (G054022)
FWO (11E0123N)
FWO (1805518N)
HORIZON EUROPE European Innovation Council (948959)
Jeffrey Modell Foundation
Innovative Medicines Initiative (grant Hippocrates)
Flemish Institute of Biotechnology (Grand Challenges project Spartacus)
- License Information
-
More Information
Article History
Received: 28 May 2023
Accepted: 14 July 2023
First Online: 7 August 2023
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Isabelle Meyts has received research funding at UZ Leuven from CSL Behring, unrelated to this study. She also participates as an advisory board member for Boehringer-Ingelheim, through LRD KU Leuven. Leuven Research and Development, the technology transfer office of KU Leuven, has received consultancy and speaker’s fees, or research grants on behalf of Rik Lories from Abbvie, Amgen (formerly Celgene), Biosplice Therapeutics (formerly Samumed), Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Sandoz, UCB, and Viatris. This study is supported by the ERN-RITA.
